Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in:

09-07-2022 | Human Immunodeficiency Virus | Original Paper

Psychometric Evaluation and Predictive Validity of an Adapted Adherence Self-Efficacy Scale for PrEP

Authors: Sarit A. Golub, Lila Starbuck, Rachel Fikslin, Kristi E. Gamarel

Published in: AIDS and Behavior | Issue 1/2023

Login to get access

Abstract

Adherence to and sustainment of HIV pre-exposure prophylaxis (PrEP) are critical to its effectiveness. Adherence self-efficacy, i.e., confidence in one’s ability to adhere to a particular medication, is a key psychological determinant of health behavior that strongly predicts HIV treatment adherence but has been understudied in PrEP research. This paper describes the psychometric evaluation and validation of the PrEP Adherence Self-Efficacy Scale (PrEP-ASES), adapted from the previously validated HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). Data are drawn from two studies conducted at a community health center, one focused on gay and bisexual cisgender men and the other on transgender women. Factor analyses support a one-factor score (eigenvalue = 6.78) that explained 75.3% of the variance, with good test–retest reliability (rs > 0.40). In both studies, higher PrEP-ASES scores were associated with PrEP uptake, adherence, and sustainment. Findings support the utility of the PrEP-ASES in research and suggest the importance of addressing self-efficacy in PrEP programs and services.
Appendix
Available only for authorised users
Literature
1.
CDC. Pre-exposure prophylaxis (PrEP). Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention; 2021.
2.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5.CrossRef
3.
4.
Cornelisse VJ, Lal L, Price B, Ryan KE, Bell C, Owen L, et al editors. Interest in switching to on-demand HIV pre-exposure prophylaxis (PrEP) among Australian users of daily PrEP: an online survey. Open forum infectious diseases. Oxford: Oxford University Press US; 2019.
5.
Jongen VW, Reyniers T, Ypma ZM, van der Loeff MFS, Davidovich U, Zimmermann HM, et al. Choosing event-driven and daily HIV pre-exposure prophylaxis—data from two European PrEP demonstration projects among men who have sex with men. J Int AIDS Soc. 2021;24(8):e25768.CrossRef
6.
Cohen SE, Kelley CF. Is the United States ready for event-driven human immunodeficiency virus preexposure prophylaxis? Oxford: Oxford University Press US; 2020. p. 256–8.
7.
Segal K, Fitch L, Riaz F, Rodrigues J, Warren M. The evolution of oral PrEP access: tracking trends in global oral PrEP use over time. HIV Research for Prevention (HIVR4P) virtual conference, abstract OA11.01, 2021.
8.
Sullivan PS, Satcher Johnson A, Pembleton ES, Stephenson R, Justice AC, Althoff KN, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. Lancet. 2021;397(10279):1095–106.CrossRef
9.
Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9): e1001511.CrossRef
10.
Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England). 2016;30(12):1973.CrossRef
11.
Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540.CrossRef
12.
Allison BA, Widman L, Stewart J, Evans R, Perry M. Adherence to pre-exposure prophylaxis in adolescents and young adults: a systematic review and meta-analysis. J Adolesc Health. 2022;70(1):28–41.CrossRef
13.
Yun K, Xu J-J, Zhang J, Li J-M, Hu Q-H, Chu Z-X, et al. Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. Sex Transm Infect. 2018;94(3):163–8.CrossRef
14.
Hojilla JC, Hurley LB, Marcus JL, Silverberg MJ, Skarbinski J, Satre DD, et al. Characterization of HIV preexposure prophylaxis use behaviors and HIV incidence among US adults in an integrated health care system. JAMA Netw Open. 2021;4(8):e2122692.CrossRef
15.
Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV—how can we improve uptake and adherence? BMC Infect Dis. 2018;18(1):1–14.CrossRef
16.
17.
Glanz KE, Rimer BK, Viswanath K. Health behavior: theory, research, and practice in health behavior. 5th ed. Hoboken: Wiley; 2015.
18.
Johnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). J Behav Med. 2007;30(5):359–70.CrossRef
19.
Bandura A. Human agency in social cognitive theory. Am Psychol. 1989;44(9):1175.CrossRef
20.
Bandura A. Regulation of cognitive processes through perceived self-efficacy. Dev Psychol. 1989;25(5):729.CrossRef
21.
Nafradi L, Nakamoto K, Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS ONE. 2017;12(10): e0186458.CrossRef
22.
Sevelius JM, Carrico A, Johnson MO. Antiretroviral therapy adherence among transgender women living with HIV. J Assoc Nurses AIDS Care. 2010;21(3):256–64.CrossRef
23.
Batey DS, Whitfield S, Mulla M, Stringer KL, Durojaiye M, McCormick L, et al. Adaptation and implementation of an intervention to reduce HIV-related stigma among healthcare workers in the United States: piloting of the FRESH workshop. AIDS Patient Care STDS. 2016;30(11):519–27.CrossRef
24.
Nakimuli-Mpungu E, Musisi S, Katabira E, Nachega J, Bass J. Prevalence and factors associated with depressive disorders in an HIV+ rural patient population in southern Uganda. J Affect Disord. 2011;135(1–3):160–7.CrossRef
25.
Zhu Y, Wu J, Feng X, Chen H, Lu H, Chen L, et al. Patient characteristics and perceived health status of individuals with HIV and tuberculosis coinfection in Guangxi, China. Medicine. 2017;96(14):e6475.CrossRef
26.
Johnson MO, Dilworth SE, Taylor JM, Darbes LA, Comfort ML, Neilands TB. Primary relationships, HIV treatment adherence, and virologic control. AIDS Behav. 2012;16(6):1511–21.CrossRef
27.
Eller L, Rivero-Mendez M, Voss J, Chen W, Chaiphibalsarisdi P, Iipinge S, et al. Depressive symptoms, self-esteem, HIV symptom management self-efficacy and self-compassion in people living with HIV. AIDS Care. 2014;26(7):795–803.CrossRef
28.
Nokes K, Johnson MO, Webel A, Rose CD, Phillips JC, Sullivan K, et al. Focus on increasing treatment self-efficacy to improve human immunodeficiency virus treatment adherence. J Nurs Scholarsh. 2012;44(4):403–10.CrossRef
29.
Qu D, Zhong X, Lai M, Dai J, Liang H, Huang A. Influencing factors of pre-exposure prophylaxis self-efficacy among men who have sex with men. Am J Mens Health. 2019;13(2):1557988319847088.CrossRef
30.
31.
Walsh JL. Applying the information–motivation–behavioral skills model to understand PrEP intentions and use among men who have sex with men. AIDS Behav. 2019;23(7):1904–16.CrossRef
32.
Poteat T, Malik M, Scheim A, Elliott A. HIV prevention among transgender populations: knowledge gaps and evidence for action. Curr HIV/AIDS Rep. 2017;14(4):141–52.CrossRef
33.
Halkitis PN, Wolitski RJ, Millett GA. A holistic approach to addressing HIV infection disparities in gay, bisexual, and other men who have sex with men. Am Psychol. 2013;68(4):261.CrossRef
34.
CDC. Pre-exposure prophylaxis for the prevention of HIV infection in the United States: a clinical practice guideline. CDC; 2014.
35.
Golub SA, Fikslin RA, Goldberg MH, Peña SM, Radix A. Predictors of PrEP uptake among patients with equivalent access. AIDS Behav. 2019;23(7):1917–24.CrossRef
36.
37.
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRef
38.
Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, Leventhal E, et al. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. Br J Health Psychol. 2013;18(1):18–30.CrossRef
39.
40.
Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med. 1983;13(3):595–605.CrossRef
41.
Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700–8.CrossRef
42.
Daughtridge G, Hebel S, Larabee L, Patani H, Cohen A, Fischl M, et al., editors. Development and clinical use case of a urine tenofovir adherence test. 2019 HIV Diagnostics Conference Abstract; 2019.
43.
Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med. 2017;18(6):412–8.CrossRef
44.
Patel RR, Amico KR, Harrison LC, Al E. Associations between urine tenofovir levels and pharmacy measures for PrEP adherence. Miami Beach: International Association of Providers of AIDS Care (IAPAC); 2017.
45.
Patel RR, Lalley-Chareczko L, Harrison LC, Anderson P, Amico KR, Presti R, et al. Evaluating urine with dried blood spots to assess tenofovir levels for PrEP adherence. Paris: International AIDS Society; 2017.
46.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.CrossRef
47.
Connor KM, Davidson JR. Development of a new resilience scale: the Connor–Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76–82.CrossRef
48.
Raykov T, Marcoulides GA. Introduction to psychometric theory. London: Routledge; 2011.CrossRef
49.
Ferrando Piera PJ, Lorenzo Seva U. Program FACTOR at 10: origins, development and future directions. Psicothema. 2017;29(2):236–40.
50.
Hau KT, Marsh HW. The use of item parcels in structural equation modelling: non-normal data and small sample sizes. Br J Math Stat Psychol. 2004;57(2):327–51.CrossRef
51.
Schumacker RE, Lomax RG. A beginner’s guide to structural equation modeling. London: Psychology Press; 2004.CrossRef
52.
Yu C-Y. Evaluating cutoff criteria of model fit indices for latent variable models with binary and continuous outcomes. Los Angeles: University of California; 2002.
53.
Brown JL, Littlewood RA, Vanable PA. Social-cognitive correlates of antiretroviral therapy adherence among HIV-infected individuals receiving infectious disease care in a medium-sized northeastern US city. AIDS Care. 2013;25(9):1149–58.CrossRef
54.
Ironson G, Weiss S, Lydston D, Ishii M, Jones D, Asthana D, et al. The impact of improved self-efficacy on HIV viral load and distress in culturally diverse women living with AIDS: the SMART/EST Women’s Project. AIDS Care. 2005;17(2):222–36.CrossRef
55.
Chesney MA, Chambers DB, Taylor JM, Johnson LM, Folkman S. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med. 2003;65(6):1038–46.CrossRef
56.
Damush T, Kroenke K, Bair M, Wu J, Tu W, Krebs E, et al. Pain self-management training increases self-efficacy, self-management behaviours and pain and depression outcomes. Eur J Pain. 2016;20(7):1070–8.CrossRef
57.
Mansouri P, Ghadami M, Najafi SS, Yektatalab S. The effect of self-management training on self-efficacy of cirrhotic patients referring to transplantation Center of Nemazee Hospital: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2017;5(3):256.
Metadata
Title
Psychometric Evaluation and Predictive Validity of an Adapted Adherence Self-Efficacy Scale for PrEP
Authors
Sarit A. Golub
Lila Starbuck
Rachel Fikslin
Kristi E. Gamarel
Publication date
09-07-2022
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2023
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-022-03758-7

Other articles of this Issue 1/2023

Examining the Relationship Between Psychosocial Factors with Knowledge of HIV-Positive Status and Antiretroviral Therapy Exposure Among Adolescent Girls and Young Women Living with HIV in South Africa

Multi-level Factors Driving Pre-exposure Prophylaxis Non-initiation Among Young Women at High Risk for HIV in Kenya

Evidence for the Role of State-Level Economic Policy in HIV Risk Reduction: State Earned Income Tax Credit Generosity and HIV Risk Behavior Among Single Mothers

Awareness, Willingness and Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers Living in Dar-es-Salaam, Tanzania

Impact of the COVID-19 Pandemic on HIV Healthcare Service Engagement, Treatment Adherence, and Viral Suppression in the United States: A Systematic Literature Review

  • Care
  • Substantive Review

Factors Associated with Exchange Sex Among Cisgender Persons Who Inject Drugs: Women and MSM—23 U.S. Cities, 2018

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits